Daegu Catholic University Medical Center

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD

  NCT07770867· Neudive Inc.· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)

  NCT07741721· Chonnam National University Hospital· Source

• Not yet recruiting

  Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation

  NCT07486739· Seoul National University Hospital· Source

• Recruiting

  A Study of E6742 in Participants With Systemic Lupus Erythematosus

  NCT07515014· Phase 2· Eisai Co., Ltd.· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD

  NCT07242625· Neudive Inc.· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

  NCT05672836· Phase 4· Duk-Woo Park, MD· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

  NCT06649240· Seoul National University Hospital· Source

• Recruiting

  Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

  NCT06603558· AbbVie· Source

• Recruiting

  Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

  NCT05831085· Duk-Woo Park, MD· Source

• Recruiting

  Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease

  NCT05829889· Seung-Jung Park· Source

• Recruiting

  OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts

  NCT06227754· Chonnam National University Hospital· Source

• Active, not recruiting

  A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT05648500· Phase 3· Viatris Innovation GmbH· Source

• Recruiting

  OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation

  NCT05418556· Phase 4· Asan Medical Center· Source

• Active, not recruiting

  Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

  NCT05222555· Phase 1/2· Incyte Corporation· Source

• Active, not recruiting

  Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation

  NCT06247280· Yuhan Corporation· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and/or Ultimaster Nagomi™ Stent in Routine Clinical Practice

  NCT04443530· Duk-Woo Park, MD· Source

• Active, not recruiting

  Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

  NCT04285086· Phase 3· PharmaEssentia· Source

• Recruiting

  Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice

  NCT03427996· Seung-Jung Park· Source

• Active, not recruiting

  IRIS-Synergy Cohort in the IRIS-DES Registry

  NCT02720419· Jung-min Ahn· Source

• Active, not recruiting

  IRIS-Onyx Cohort in the IRIS-DES Registry

  NCT02593994· Seung-Jung Park· Source

• Recruiting

  Observational Study for Left Main Disease Treatment

  NCT01341327· Seung-Jung Park· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease8 recruiting
• Autism2 recruiting
• Stroke2 recruiting
• Acute myeloid leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Heart failure1 recruiting
• Lupus (SLE)1 recruiting
• Migraine1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD

  NCT06446193· Neudive Inc.· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

  NCT05718375· Phase 2· Curacle Co., Ltd.· Source

• Completed

  Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

  NCT07564726· Phase 3· Celltrion Pharm, Inc.· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Coherus Oncology, Inc.· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

  NCT04541810· AbbVie· Source

• Terminated

  Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke

  NCT04624646· Ewha Womans University Mokdong Hospital· Source

• Completed

  Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

  NCT04433442· AbbVie· Source

• Completed

  Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia

  NCT06293261· Yuhan Corporation· Source

• Completed

  Resolution of Thrombi in Left Atrial Appendage With Edoxaban

  NCT03840291· Phase 4· Keimyung University Dongsan Medical Center· Source

• Completed

  Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

  NCT03776123· Ipsen· Source

• Completed

  Post Marketing Surveillance Study for ADYNOVATE in South Korea

  NCT03824522· Takeda· Source

• Completed

  TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI

  NCT03465644· Phase 4· Duk-Woo Park, MD· Source

• Completed

  Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

  NCT03288974· Celgene· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

• Terminated

  A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

  NCT02841540· Phase 1· Hemavant Sciences GmbH· Source

• Completed

  IRIS Ultimaster Cohort in the IRIS-DES Registry

  NCT02719106· Duk-Woo Park, MD· Source

• Terminated

  Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice

  NCT02622100· Duk-Woo Park, MD· Source

• Completed

  XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice

  NCT02042300· Seung-Jung Park· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Haemophilia6 works · 1 trial
• High blood pressure6 works · 2 trials